<DOC>
	<DOCNO>NCT00457652</DOCNO>
	<brief_summary>Does caffeine reduce rosuvastatin induced protection ischemia reperfusion injury ?</brief_summary>
	<brief_title>Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury ?</brief_title>
	<detailed_description>Rosuvastatin proven cholesterol lower medicine , hereby assume achieve reduction cardiovascular event . Apart 's cholesterol lower action , rosuvastatin may also increase tolerance ischemia-reperfusion injury . In dog rosuvastatin increase endogenous concentration adenosine , enhance activity enzyme ecto-5'-nucleotidase , convert adenosine monophosphate adenosine . We hypothesize rosuvastatin increase tolerance ischemia-reperfusion injury induction ecto-5'-nucleotidase thereby increase adenosine activity . This protective effect rosuvastatin abrogate use adenosine receptor antagonist caffeine .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Male age 1850 yr sign informed consent Cardiovascular disease Hypertension ( systole &gt; 140 mmHg , diastole &gt; 90 mmHg ) Hypercholesterolemia ( fast total cholesterol &gt; 6,0 mmol/l ) Drug abuse Concomitant medication use Inability perform ischemic isometric muscle contraction Diabetes Mellitus ( fast glucose &gt; 7.0 mmol/L random glucose &gt; 11.0 mmol/L ) AlanineAminoTransferase ( ALAT ) &gt; 90U/L ( twice upper level normal range ) Creatinine Kinase ( CK ) &gt; 340U/L ( twice upper level normal range ) Participation trial concern medicinal product last 60 day prior study . Participation clinical trial involve</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Rosuvastatin</keyword>
	<keyword>Caffeine</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Reperfusion</keyword>
</DOC>